Search results
Results from the WOW.Com Content Network
Weight gain [18] There has been a study that suggests antipsychotics are associated with possible cortical reconfiguration and gray matter loss, [19] but correlational data also suggests patients who consume antipsychotics, like people with schizophrenia, tend to engage in unhealthy habits like smoking which may exacerbate gray matter loss. [20]
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine) and the sixth least sedation (after paliperidone, sertindole ...
According to the manufacturer insert, ziprasidone caused an average weight gain of 2.2 kg (4.8 lbs), which is significantly lower than other atypical antipsychotics, making this medication better for patients that are concerned about their weight.
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. [11] [13] [14] The most common side effects include akathisia (a constant urge to move) and weight gain. [12]
Produces roughly as much weight gain as risperidone, less weight gain than clozapine, olanzapine and zotepine and more weight gain than ziprasidone, lurasidone, aripiprazole and asenapine. [22] As with many other atypical antipsychotics, this action is likely due to its actions at the H 1 histamine receptor and 5-HT 2C receptor. [10]
Paliperidone, sold under the brand name Invega among others, is an atypical antipsychotic. [14] It is indicated in the treatment of schizophrenia and schizoaffective disorder . [ 14 ] It is marketed by J&J Innovative Medicine
[1] [2] [3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect. [4] [5] Although Lybalvi still produces transient weight gain of roughly 11 pounds, its metabolic profile is significantly lower than olanzapine alone. The formulation was approved for medical use in the ...